Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation - PubMed (original) (raw)
Case Reports
. 2005 Oct 15;106(8):2865-70.
doi: 10.1182/blood-2005-04-1568. Epub 2005 Jun 21.
Caroline Berubé, Joseph D Growney, Ching-Cheng Chen, Tracy I George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L Lilleberg, Jeffrey A Durocher, Jack H Lichy, Yanfeng Wang, Pamela S Cohen, Daniel A Arber, Michael C Heinrich, Len Neckers, Stephen J Galli, D Gary Gilliland, Steven E Coutré
Affiliations
- PMID: 15972446
- PMCID: PMC1895309
- DOI: 10.1182/blood-2005-04-1568
Case Reports
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Jason Gotlib et al. Blood. 2005.
Abstract
The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease.
Figures
Figure 1.
Peripheral blood and bone marrow findings before and after treatment with PKC 412. (A-F) Before treatment. (G-I) After treatment. (A) Circulating mast cell (arrow, left) and dysplastic nucleated red blood cell (arrowhead, right) in peripheral blood. Wright-Giemsa, 1000 ×. (B) Hypercellular bone marrow with aggregates of pale-staining mast cells surrounding a dilated sinus (*). Hematoxylin and eosin, 40 ×. (C) Whorled nodule of mast cells with characteristic clear cytoplasm including spindled forms. Hematoxylin and eosin, 400 ×. (D) Increased mast cells show a nodular and interstitial pattern in the bone marrow occupying approximately 70% marrow cellularity. Mast cell tryptase, 40 ×. (E) The majority of mast cells are highlighted by CD25 antibody. CD25, 40 ×. (F) Few numbers of CD34-positive blasts (∼5%) detected on bone marrow biopsy. CD34, 400 ×. (G) The posttreatment bone marrow shows a similar mast cell burden as seen prior to treatment. Mast cell tryptase, 40 ×. (H) A slight decrease in CD25-positive mast cells (∼40% of marrow cellularity) is noted after therapy. CD25, 40 ×. (I) Increased numbers of CD34-positive blasts (10%-20%) in bone marrow biopsy indicating progression of this patient's AHNDMD, MDS/MPD. CD34, 400 ×.
Figure 2.
Changes in the pharmacokinetics of PKC412 and patient mast cell disease-related parameters during PKC412 therapy. (A) Trough plasma concentration-time profiles of PKC412 and its major active metabolite CGP62221 and the sum of PKC412 and CGP62221 in the mast cell leukemia patient receiving PKC412 100 mg twice a day between day 1 and day 90, and 75 mg three times a day starting from day 90. (B) Serum histamine level and percent peripheral blood mast cells quantified by manual differential. (C) Normalized phospho-KIT/total KIT optical density ratio. The number of samples analyzed at each time point is shown in parentheses. (D) Semiquantitative DHPLC determination of the D816V KIT mutation frequency in the bone marrow and peripheral blood.
Figure 3.
Ba/F3-KIT D816V is sensitive to PKC-412 but not to imatinib. Plotted is the percentage of 3H-thymidine incorporation in drug-treated wells relative to no drug controls. Cells were treated with imatinib (dashed lines, ○) or PKC412 (solid line, •) for 24 hours in the presence of 10 ng/mL IL-3 and the absence of recombinant human stem cell factor (SCF). Plotted is the percent 3H-thymidine incorporation in drug-treated wells relative to no drug controls. Data are the mean of triplicates (plot standard deviation). PKC412 IC50 30 nM-40 nM.
Similar articles
- PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27. Blood. 2006. PMID: 16189265 - Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Haematologica. 2007 Nov;92(11):1451-9. doi: 10.3324/haematol.11339. Haematologica. 2007. PMID: 18024392 - Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O. Georgin-Lavialle S, et al. Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28. Eur J Haematol. 2012. PMID: 22324351 - Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C, DeRemer DL, Akin C. Ustun C, et al. Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Leuk Res. 2011. PMID: 21641642 Review. - Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W, Gotlib J. Shomali W, et al. Int J Mol Sci. 2021 Mar 15;22(6):2983. doi: 10.3390/ijms22062983. Int J Mol Sci. 2021. PMID: 33804174 Free PMC article. Review.
Cited by
- Beyond the Usual Suspects: Unraveling Spleen Mastocytosis in Hypersplenism Differential Diagnosis.
Silva IF, Monteiro-Brás T, Araújo I, Caldeira B, Rua Coelho R, Rodrigues A, Fernandes I, Xavier Pires S, Cabral R. Silva IF, et al. Cureus. 2024 Aug 18;16(8):e67124. doi: 10.7759/cureus.67124. eCollection 2024 Aug. Cureus. 2024. PMID: 39156991 Free PMC article. - Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
Veitch S, Radia DH. Veitch S, et al. Diagnostics (Basel). 2023 Dec 29;14(1):80. doi: 10.3390/diagnostics14010080. Diagnostics (Basel). 2023. PMID: 38201389 Free PMC article. Review. - Recent advances in diagnosis and therapy in systemic mastocytosis.
Lee HJ. Lee HJ. Blood Res. 2023 Apr 30;58(S1):96-108. doi: 10.5045/br.2023.2023024. Blood Res. 2023. PMID: 37105564 Free PMC article. Review. - Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J. Gotlib J. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):34-46. doi: 10.1182/hematology.2022000368. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485158 Free PMC article. Review. - Clinical challenge for gastroenterologists-Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review.
Elvevi A, Elli EM, Lucà M, Scaravaglio M, Pagni F, Ceola S, Ratti L, Invernizzi P, Massironi S. Elvevi A, et al. World J Gastroenterol. 2022 Aug 7;28(29):3767-3779. doi: 10.3748/wjg.v28.i29.3767. World J Gastroenterol. 2022. PMID: 36157547 Free PMC article. Review.
References
- Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) classification of tumours: pathology & genetics: tumours of haematopoietic and lymphoid tissues. Vol. 2. Geneva, Switzerland: WHO; 2001: 291-302.
- Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122: 695-717. - PubMed
- Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55: 1-96. - PubMed
- Longley BJ, Tyrrell L, Lu Sz, et al. Somatic c-KIT activating mutation in uticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12: 312-314. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA66996/CA/NCI NIH HHS/United States
- DK50654/DK/NIDDK NIH HHS/United States
- K23HL04409/HL/NHLBI NIH HHS/United States
- AI-41995/AI/NIAID NIH HHS/United States
- AI-23990/AI/NIAID NIH HHS/United States
- CA-72074/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous